G*****t

Diclofenac monitoring requirements are mainly about catching blood pressure, kidney, liver, blood, and fluid-retention problems early rather than waiting for symptoms. In official diclofenac labeling, blood pressure should be monitored during the start of NSAID treatment and throughout therapy, because diclofenac can worsen hypertension and contribute to cardiovascular risk. Renal function monitoring is especially important in people with renal or hepatic impairment, heart failure, dehydration, hypovolemia, or advanced kidney disease risk, since diclofenac can worsen renal function. Liver monitoring also matters because diclofenac has a known risk of liver injury; labeling for diclofenac products recommends liver-related monitoring, and older diclofenac gel labeling specifically identifies ALT as the preferred marker for monitoring liver injury.

In practical terms, the usual monitoring framework for diclofenac monitoring requirements includes checking blood pressure after initiation and periodically thereafter, reviewing kidney function when the patient has renal risk factors or is on prolonged treatment, and following liver enzymes if treatment is ongoing or if symptoms suggest hepatic injury. Clinicians also watch for edema, heart failure worsening, gastrointestinal bleeding, and reduced response to ACE inhibitors, thiazides, or loop diuretics. If therapy is long-term, it is common to also follow a CBC and chemistry profile periodically to look for anemia or other NSAID-related toxicity, although the most explicit recurring label requirements center on blood pressure, renal function in at-risk patients, and liver safety.